Examining Genetic Associations in Neurodegenerative Diseases
- PI
- Greicius, Michael
- DAR ID
- 10018
- Initial Approval Date
- January 10, 2019
- Current DAR Status
- Active
- PI Institution
- Stanford University School of Medicine
- PI Institution Country
- United States
- PI Institution Type
- Non-Profit
Requested Datasets (41)
NG00067Alzheimer's Disease Sequencing Project Umbrella StudyNG00108Profiling microglia expression profiles in AD using single-nuclei RNA-seqNG00105MiGA – Microglia Genomic AtlasNG00106LASI-DAD Genotyping Chip Data (Illumina Infinium GSA-24 v2.0), Imputed Data (1000 Genomes Phase 3 v5 and TOPMed r2)NG00113Metabolomic and lipidomic signatures in Alzheimer disease brainsNG00114DNA Methylation in Alzheimer disease brainsNG00104Dataset from Clinical and Pathological Studies in the Oldest Old (90+ Study)NG00119Health and Retirement Study Genotype Data 2006-2012NG00121Alzheimer’s disease single-neuron whole-genome sequencing - Miller 2022NG00117NCRAD Families GWASNG00127A longitudinal study of Alzheimer's Disease and other dementing illnesses – KnightADRC GWASNG00128Proteomic profiling identified plasma biomarkers for SARS-CoV-2 infection and severity of COVID-19 patients
Show more
NG00129NCRAD Families Whole Exome SequencingNG00126A fast and robust strategy to remove variant level artifacts in Alzheimer’s Disease Sequencing Project data (Belloy et al. 2022)NG00132Health and Retirement Study (HRS) APOE and Serotonin Transporter AllelesNG00118AMP-AD SV WGS and SV-xQTLNG00134National Health and Aging Trends Study (NHATS) GWASNG00130Large scale CSF proteogenomic atlasNG00144The Prediction of Alzheimer’s Disease through Multi-Trait Genetic ModelingNG00131Large scale genetics study on CSF and brain metabolite levelsNG00135UAB ADRC - University of Alabama at Birmingham Alzheimer’s Disease Research CenterNG00102Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disordersNG00154Dementia in Parkinson's Disease(PDD)NG00153Health and Retirement Study (HRS) DNA MethylationNG00160Sex-specific genetic architecture of late-life memory performanceNG00022ADC1 - Alzheimer's Disease Center Dataset 1NG00023ADC2 - Alzheimer's Disease Center Dataset 2NG00024ADC3 - Alzheimer's Disease Center Dataset 3NG00068ADC4 - Alzheimer's Disease Center Dataset 4NG00069ADC5 - Alzheimer's Disease Center Dataset 5NG00070ADC6 - Alzheimer's Disease Center Dataset 6NG00071ADC7 - Alzheimer's Disease Center Dataset 7NG00136ADC8 - Alzheimer's Disease Center Dataset 8NG00137ADC9 - Alzheimer's Disease Center Dataset 9NG00138ADC10 - Alzheimer's Disease Center Dataset 10NG00139ADC11 - Alzheimer's Disease Center Dataset 11NG00140ADC12 - Alzheimer's Disease Center Dataset 12NG00149ADC13 - Alzheimer's Disease Center Dataset 13NG00150ADC14 - Alzheimer's Disease Center Dataset 14NG00151ADC15 - Alzheimer's Disease Center Dataset 15NG00159Longitudinal Change in Memory Performance as a Strong Endophenotype for Alzheimer’s Disease – Archer, et al, 2023
Research Use Statement
We are studying the effects of rare (minor allele frequency < 5%) genetic variants on the risk of developing late-onset Alzheimer’s Disease (AD). We are interested in variants that have a protective effect in subjects who are at an increased genetic risk, or variants that lead to multiple dementias. Our aim is to identify any genetic variants that are present in the “case” group but not the “AD control” groups for both types of variants. The raw data we receive will be annotated to identify SNP locations and frequencies using existing databases such as 1,000 Genomes. We will filter the data based on genetic models such as compounded heterozygosity, recessive and dominant models to identify different types of variants.
Non-Technical Summary
Current genetic understanding of Alzheimer’s Disease (AD) does not fully explain its heritability. The APOE4 allele is a well-established risk factor for the development of Alzheimer’s Disease (AD). However, some individuals who carry APOE4 remain cognitively healthy until advanced ages. Additionally, the cause of mixed dementia pathology development in individuals remains largely unexplained. We aim to identify genetic factors associated with these “protected” and mixed pathology phenotypes.
Reported Publications
Publications shown are those reported by investigators through NIAGADS DAR reporting and renewal processes and may not represent a complete list of publications associated with the project.
No publications have been reported for this DAR.